Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and clinical impact of
15-grams daily of sodium phenylbutyrate (phenylbutyrate) in Huntington's disease and to lay
the groundwork for possible subsequent trials designed to specifically address its ability to
slow or halt the progression of the disease.
Phase:
Phase 2
Details
Lead Sponsor:
University of Rochester
Collaborators:
Columbia University HP Therapeutics Foundation Johns Hopkins University Massachusetts General Hospital University of Alabama at Birmingham University of California, San Diego University of Iowa University of Kansas